MedTrace Logo

D-Ribose for Fatigue in Subjects With Fibromyalgia

NCT01315210 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2013-09-18

No results posted yet for this study

Summary

To evaluate the safety and to determine the efficacy of D-ribose for the amelioration of fatigue in subjects with fibromyalgia. This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center, multiple dose study of D-ribose versus placebo administered at doses of 5 g three times a day (TID) over a 12-week period to subjects who are experiencing fatigue associated with a diagnosis of fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DRUG

D-Ribose Powder

5 g TID for 12 Weeks

DIETARY_SUPPLEMENT

Placebo Powder

5 g TID for 12 Weeks

Sponsors & Collaborators

  • RiboCor, Inc.

    lead INDUSTRY

Principal Investigators

  • Leslie Crofford, MD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01315210 on ClinicalTrials.gov